Cardarine (GW-501516)
PPAR-δ agonist (GW-501516 — NOT a SARM)
Also known as GW-501516, GW501516, cardarine, endurobol
Half-life
~16-24 hours
What is Cardarine (GW-501516)?
PPAR-delta agonist (not technically a SARM) known for endurance and fat oxidation effects.
How Cardarine (GW-501516) works
Activates PPAR-delta pathways to increase fatty-acid oxidation and mitochondrial efficiency.
Benefits & uses
- Endurance / stamina boost
- Fat oxidation (cutting)
- Non-hormonal (no suppression)
- No PCT needed
Common uses: Endurance, fat oxidation, exercise capacity, lipid profile support.
Cardarine (GW-501516) dosage
Protokol doesn't recommend doses for prescription or controlled compounds. Any figures below are reference or observational reports — dosing should be set with a qualified clinician.
- Commonly reported
- Observational: ~10–20 mg/dayObservational use reports — not a recommendation.
Cardarine (GW-501516) half-life
~16-24 hours
Cardarine (GW-501516) side effects
Animal data shows tumor risk at chronic high exposures; human long-term safety unknown.
- Potential long-term carcinogenicity concern
- Headache
- GI discomfort (uncommon)
- Non-suppressive (an advantage)
- 🔴 CANCER concern — animal studies showed tumor development at high doses (why the drug was abandoned in development)
Warnings & monitoring
- 🔴 Development was HALTED due to cancer in animal studies — this is the defining safety concern, not suppression. Educational reference only
- FDA-warned / WADA-banned / gray-market
- Not approved for human use
Preparation & storage
- Storage
- Room temperature.
Cardarine (GW-501516) interactions
with Ostarine
Caution · moderateOstarine is relatively mild; GW501516 is a PPARδ agonist associated with carcinogenicity in animal studies. Human risk unknown but significant enough to warrant caution.
Timing: GW501516 (Cardarine) has been discontinued in research due to cancer findings in animal studies
with Testosterone
Caution · moderateCardarine (GW501516) is a PPARδ agonist discontinued from human trials due to carcinogenicity in animals. While used in performance circles, human carcinogenic risk remains unestablished.
Timing: GW501516 has been associated with cancer in animal studies — risk-benefit assessment required
with Testosterone
Caution · moderateWhile Cardarine is popular for endurance and fat loss alongside testosterone cycles, human carcinogenicity data is lacking following concerning animal studies. Risk tolerance is individual.
Timing: See GW501516 animal carcinogenicity data before use
with LGD-4033
CompatibleLGD-4033 drives strength and lean mass; Cardarine offsets the cardiovascular impact and supports conditioning.
Timing: Co-administer daily for lean bulk or recomp
with Ostarine
CompatibleA popular mild body recomposition stack. Ostarine preserves muscle during a cut while Cardarine boosts fat oxidation and endurance. Minimal androgenic side effects at these doses.
Timing: Daily; Cardarine 20 mg, Ostarine 10–25 mg
with Ostarine
CompatibleCardarine boosts endurance and fat oxidation while Ostarine preserves lean mass on a deficit — a well-studied recomp stack.
Timing: Both daily during recomp/cut cycles, 8–12 weeks
with RAD-140
CompatibleCardarine (GW-501516) is not a SARM but a PPAR-delta agonist — it has no androgenic activity and complements RAD-140's anabolic effects with enhanced endurance and fat oxidation.
Timing: Take both daily; Cardarine pre-workout, RAD-140 in the morning
with SR9009
Compatible · lowSR9009 (Stenabolic) is a Rev-Erb agonist improving metabolic rate and endurance via circadian rhythm modulation; Cardarine activates PPARδ for fat oxidation. Complementary endurance/fat loss stack.
Timing: Both taken multiple times per day due to short half-lives (4–5h); pre-workout ideal
with Telmisartan
CompatibleTelmisartan's PPAR-gamma activation complements Cardarine's PPAR-delta agonism and helps control AAS-driven BP elevation.
Timing: Telmisartan 40mg daily during Cardarine + harsh AAS cycles
